Last $4.73 USD
Change Today +0.45 / 10.51%
Volume 1.9M
AMPE On Other Exchanges
Symbol
Exchange
NYSE Amex
Munich
As of 8:04 PM 01/23/15 All times are local (Market data is delayed by at least 15 minutes).

ampio pharmaceuticals inc (AMPE) Snapshot

Open
$4.32
Previous Close
$4.28
Day High
$4.90
Day Low
$4.16
52 Week High
02/11/14 - $9.36
52 Week Low
11/13/14 - $3.19
Market Cap
245.8M
Average Volume 10 Days
767.7K
EPS TTM
$-0.76
Shares Outstanding
52.0M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for AMPIO PHARMACEUTICALS INC (AMPE)

Related News

No related news articles were found.

ampio pharmaceuticals inc (AMPE) Related Businessweek News

No Related Businessweek News Found

ampio pharmaceuticals inc (AMPE) Details

Ampio Pharmaceuticals, Inc., a development stage biopharmaceutical company, develops therapies for the treatment of prevalent inflammatory conditions in the United States. The company is developing compounds that decrease inflammation by inhibiting specific pro-inflammatory compounds by affecting specific pathways at the protein expression and at the transcription level; activating specific phosphatase or depletion of the available phosphate needed for the inflammation process; and decreasing vascular permeability. Its lead product candidates in development include Ampion, which is in Phase III clinical trial for osteoarthritis of the knee and Optina that is in Phase IIb clinical trial for diabetic macular edema. The company, through its subsidiaries, is also involved in the development and commercialization of RedoxSYS, an in-vitro diagnostic platform that measures human oxidation-reduction potential; and Zertane, an oral drug in late stage development as treatment for premature ejaculation in men. Ampio Pharmaceuticals, Inc. is headquartered in Greenwood Village, Colorado.

16 Employees
Last Reported Date: 02/14/14

ampio pharmaceuticals inc (AMPE) Top Compensated Officers

Founder, Chairman and Chief Executive Officer
Total Annual Compensation: $376.3K
Chief Operating Officer
Total Annual Compensation: $356.5K
Chief Regulatory Affairs Officer
Total Annual Compensation: $380.0K
Chief Scientific Officer and Director
Total Annual Compensation: $455.0K
Compensation as of Fiscal Year 2013.

ampio pharmaceuticals inc (AMPE) Key Developments

Ampio Pharmaceuticals, Inc. Presents at 7th annual Biotech Showcase Conference 2015, Jan-13-2015 11:30 AM

Ampio Pharmaceuticals, Inc. Presents at 7th annual Biotech Showcase Conference 2015, Jan-13-2015 11:30 AM. Venue: Parc 55 Wyndham San, Francisco - Union Square, San Francisco, CA 94102, United States. Speakers: Jarrett Disbrow, President and Chief Executive Officer.

Ampio Pharmaceuticals, Inc. Announces Results of the Open Label Portion of the Multiple Intra-Articular Injections (STRUT) Study of Ampion(TM) in Patients with Osteoarthritis of the Knee at Week Twenty of the Trial

Ampio Pharmaceuticals, Inc. announced updates for the STRUT open label portion (n=7) of the multiple injection study at week 20 of the study. The seven (7) patient 'open label' phase of the 47 patient STRUT study was performed to assure that multiple injections of Ampion(TM) were safe. Each patient received three 4ml intra-articular injections of Ampion(TM), one at baseline, the second at 2 weeks and the third at 4 weeks. There were no drug related serious adverse events reported during the first 20 weeks of this current trial; the further results of this open label phase are as follows: WOMAC A: The primary endpoint, WOMAC A pain score, improved by 91.2% from baseline to 20 weeks. The WOMAC A mean (SD) significantly improved from 2.27 (0.59) at baseline, to 0.20 (0.23) at week 20, mean difference (95% CI) -2.03 (-2.83,-1.23), p=0.001; WOMAC B: The secondary endpoint measurement of stiffness, also improved significantly by 87% from baseline at week 20 from mean (SD) of 2.75 (0.82) to 0.36 (0.48), mean difference (95% CI) --2.33 (-3.51,-1.15) p=0.004; WOMAC C: The secondary endpoint of a validated measure of simple daily physical functions improved by 91.3% from baseline at week 20. This improvement was statistically significant, going from 2.32 (0.60) at baseline to 0.20 (0.34) at week 20; mean (95% CI) improvement of --2.09 (-2.96,-1.21), p=0.002.

Ampio Pharmaceuticals, Inc. Announces Updates for the STRUT and STRIDE Multiple Injection Studies

Ampio Pharmaceuticals, Inc. announced updates for the STRUT and STRIDE multiple injection studies that are proceeding simultaneously. The seven patient 'open label' phase of the 47 patient STRUT study was performed to assure that multiple injections of Ampion(TM) were safe. Each patient received three 4ml intra-articular injections of Ampion(TM), one at baseline, the second at 2 weeks and the third at four weeks. In addition, every patient received a high resolution MRI prior to the first injection and eight weeks after the last injection. There were no drug related serious adverse events reported during the first 12 weeks of this current trial. The further results of this open label phase are: WOMAC A: This primary endpoint pain score for the 7 patients improved by 95% from baseline at 12 weeks. (WOMAC A mean (SD) improved from 2.27(0.59) at baseline to 0.11(0.23) at week 12, mean difference (95% CI) -2.11(-2.71,-1.52), p=0.0001). In comparison, the WOMAC A pain score for the SPRING study improved by 42% at the same time point. WOMAC B: This secondary endpoint measurement of stiffness, also improved significantly by 89% from baseline at week 12 (from mean (SD) of 2.75(0.82) to 0.29(0.49), mean difference (95% CI) -2.43(-3.16,-1.70) p=0.0002). In comparison the WOMAC B score in the SPRING study showed no improvement over baseline at the same time point. WOMAC C: This secondary endpoint of a validated measure of simple daily physical functions improved by 92% from baseline at week 12 (WOMAC C mean (SD) improved from 2.37(0.55) to 0.19(0.23), mean difference (95% CI) -2.16(-2.83,-1.49), p=0.0002). In comparison, the WOMAC C score in the Spring Study improved by 22% at the same time point. PATIENT'S GLOBAL ASSESSMENT of DISEASE Severity (PGA): As measured by the 5 point Likert score, this secondary endpoint improved significantly by 59% from baseline at week 12 (PGA from mean (SD) 3.50(0.84) to 1.43(0.53), mean difference (95% CI) -2.14(-3.27,-1.02) p=0.003). In comparison the PGA score in the Spring Study improved by 33% at the same time point.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
AMPE:US $4.73 USD +0.45

AMPE Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for AMPE.
View Industry Companies
 

Industry Analysis

AMPE

Industry Average

Valuation AMPE Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 3,622.4x
Price/Book 3.4x
Price/Cash Flow NM Not Meaningful
TEV/Sales 2,791.3x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact AMPIO PHARMACEUTICALS INC, please visit www.ampiopharma.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.